An international collaborative study to discontinue Imatinib/Glivec in pediatric CML patients with sustained complete molecular response
Phase of Trial: Phase II
Latest Information Update: 25 Jun 2016
At a glance
- Drugs Imatinib (Primary) ; Protein tyrosine kinase inhibitors
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms STOPIMAPED
- 01 Dec 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-006239-44).
- 02 Oct 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
- 18 Jun 2012 New trial record